Allergan PLC (NYSE:AGN) has earned an average rating of “Buy” from the twenty-five analysts that are currently covering the firm. Seven analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $296.59.
Several analysts have commented on AGN shares. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Allergan PLC in a research note on Wednesday, July 6th. Leerink Swann lifted their target price on shares of Allergan PLC from $272.00 to $294.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 27th. JPMorgan Chase & Co. set a $325.00 target price on shares of Allergan PLC and gave the stock a “buy” rating in a research note on Friday, August 5th. Zacks Investment Research lowered shares of Allergan PLC from a “buy” rating to a “hold” rating in a report on Tuesday, July 26th. Finally, Vetr upgraded shares of Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $285.60 price target on the stock in a report on Monday, August 1st.
Several large investors have recently made changes to their positions in AGN. Barnett & Company Inc. acquired a new stake in shares of Allergan PLC during the first quarter worth $111,000. Livingston Group Asset Management CO operating as Southport Capital Management acquired a new stake in shares of Allergan PLC during the second quarter worth $125,000. Trust Co. of Vermont increased its stake in shares of Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock worth $126,000 after buying an additional 89 shares in the last quarter. Ropes Wealth Advisors LLC increased its stake in shares of Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock worth $133,000 after buying an additional 58 shares in the last quarter. Finally, Integrated Investment Consultants LLC increased its stake in shares of Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock worth $137,000 after buying an additional 154 shares in the last quarter. 85.19% of the stock is owned by institutional investors and hedge funds.
Shares of Allergan PLC (NYSE:AGN) opened at 239.36 on Friday. The stock has a market cap of $94.78 billion, a price-to-earnings ratio of 22.79 and a beta of 0.73. The stock’s 50 day moving average price is $244.09 and its 200-day moving average price is $241.66. Allergan PLC has a 52-week low of $195.50 and a 52-week high of $322.68.
Allergan PLC (NYSE:AGN) last released its earnings results on Monday, August 8th. The company reported $3.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.34 by $0.01. The firm earned $3.68 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Allergan PLC had a net margin of 28.06% and a return on equity of 7.67%. Allergan PLC’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period in the previous year, the company earned $4.41 EPS. On average, analysts predict that Allergan PLC will post $14.01 earnings per share for the current fiscal year.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.